Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Zura Bio ( (ZURA) ) is now available.
On December 29, 2025, Zura Bio Limited entered into a new Letter Agreement with Athanor Capital and, on the same date, executed settlement and release agreements with Stone Peach and BAFFX17, terminating all outstanding agreements with those parties and securing broad releases of claims in favor of Zura Bio, its subsidiaries and affiliates. Following an internal review conducted by an independent Audit Subcommittee, which was formed and reported on in 2025, the board determined that replacing the Stone Peach arrangements with the Athanor Agreement was more commercially advantageous for the company and its shareholders, and that voiding or terminating the Stone Peach and BAFFX17 agreements would cleanly reset those relationships without financial restatements or findings of employee misconduct; the company now plans incremental enhancements to its internal controls and disclosure procedures that are not expected to materially alter its existing control framework.
The most recent analyst rating on (ZURA) stock is a Hold with a $5.50 price target. To see the full list of analyst forecasts on Zura Bio stock, see the ZURA Stock Forecast page.
Spark’s Take on ZURA Stock
According to Spark, TipRanks’ AI Analyst, ZURA is a Neutral.
Overall score is held back primarily by weak financial performance (no revenue, widening losses, and substantial cash burn despite zero debt). Technicals provide some support due to a strong uptrend and positive MACD, but overbought RSI/Stoch readings raise near-term risk. Valuation remains difficult to support with a negative P/E and no dividend yield provided.
To see Spark’s full report on ZURA stock, click here.
More about Zura Bio
Zura Bio Limited operates in the biopharmaceutical sector, focusing on the development of therapies through strategic collaborations and financing arrangements with investment and advisory counterparties. The company’s operations and capital structure are influenced by a range of commercial agreements with financial partners and service providers, which are overseen by its board and audit committee to ensure alignment with shareholder interests and regulatory standards.
Average Trading Volume: 632,541
Technical Sentiment Signal: Hold
Current Market Cap: $340.7M
Find detailed analytics on ZURA stock on TipRanks’ Stock Analysis page.